Article Text
Statistics from Altmetric.com
- Age-related macular degeneration
- corneal endothelium
- ranibizumab
- specular microscopy
- vascular endothelial growth factor-A
- cornea
- angiogenesis
Ranibizumab (rhuFabV2, Lucentis; Genentech, San Francisco, California) is a humanised monoclonal antibody fragment, designed to bind all isoforms of human vascular endothelial growth factor-A (VEGF-A) by preventing the interaction of VEGF-A with its receptors VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR).
Although the pharmacokinetic profile of ranibizumab after intravitreal injection in humans has not been determined definitively, ranibizumab has been detected in the aqueous humour after intravitreal standard injections in a rabbit model.1 Moreover, VEGF and its receptors were expressed in the corneal endothelium.2–5 Therefore, ranibizumab in the aqueous humour after intravitreal injections may affect the function of VEGF in the corneal endothelium, being potentially cytotoxic to human corneal endothelial cells. In the present study, we analyse the effect of the …
Footnotes
Competing interests None.
Ethics approval Ethics approval was provided by the University Hospital Principe de Asturias. Madrid (Spain).
Patient consent Obtained.
Provenance and peer review Not commissioned; not externally peer reviewed.